A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
Clinical trial NCT05600920 · RECRUITING
Trial details
- NCT number
- NCT05600920
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-06
- Primary completion
- 2026-11-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.